Leukemia stem cells (LSCs) in individuals with chronic myelogenous leukemia (CML) (hereafter referred to as CML LSCs) are responsible for initiating and maintaining clonal hematopoiesis. These cells persist in the bone marrow (BM) despite effective inhibition of BCR–ABL kinase activity by tyrosine kinase inhibitors (TKIs). Here we show that although the microRNA (miRNA) miR-126 supported the quiescence, self-renewal and engraftment capacity of CML LSCs, miR-126 levels were lower in CML LSCs than in long-term hematopoietic stem cells (LT-HSCs) from healthy individuals. Downregulation of miR-126 levels in CML LSCs was due to phosphorylation of Sprouty-related EVH1-domain-containing 1 (SPRED1) by BCR–ABL, which led to inhibition of the RAN–exportin-5–RCC1 complex that mediates miRNA maturation. Endothelial cells (ECs) in the BM supply miR-126 to CML LSCs to support quiescence and leukemia growth, as shown using mouse models of CML in which Mir126a (encoding miR-126) was conditionally knocked out in ECs and/or LSCs. Inhibition of BCR–ABL by TKI treatment caused an undesired increase in endogenous miR-126 levels, which enhanced LSC quiescence and persistence. Mir126a knockout in LSCs and/or ECs, or treatment with a miR-126 inhibitor that targets miR-126 expression in both LSCs and ECs, enhanced the in vivo anti-leukemic effects of TKI treatment and strongly diminished LSC leukemia-initiating capacity, providing a new strategy for the elimination of LSCs in individuals with CML.

  • Subscribe to Nature Medicine for full access:



Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.


Primary accessions

Gene Expression Omnibus


  1. 1.

    Chronic myeloid leukemia. N. Engl. J. Med. 340, 1330–1340 (1999).

  2. 2.

    et al. Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia. Cancer Cell 21, 577–592 (2012).

  3. 3.

    et al. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood 118, 5565–5572 (2011).

  4. 4.

    et al. Attenuation of miR-126 activity expands HSC in vivo without exhaustion. Cell Stem Cell 11, 799–811 (2012).

  5. 5.

    et al. Attenuation of microRNA-126 expression that drives CD34+38 stem–progenitor cells in acute myeloid leukemia leads to tumor eradication. Cancer Res. 74, 2094–2105 (2014).

  6. 6.

    et al. Targeting leukemia stem cells in vivo with antagomiR-126 nanoparticles in acute myeloid leukemia. Leukemia 29, 2143–2153 (2015).

  7. 7.

    et al. Overexpression and knockout of miR-126 both promote leukemogenesis. Blood 126, 2005–2015 (2015).

  8. 8.

    et al. miR-126 regulates distinct self-renewal outcomes in normal and malignant hematopoietic stem cells. Cancer Cell 29, 602–606 (2016).

  9. 9.

    et al. Attribution of vascular phenotypes of the murine Egfl7 locus to the microRNA miR-126. Development 135, 3989–3993 (2008).

  10. 10.

    et al. Distinct bone marrow blood vessels differentially regulate hematopoiesis. Nature 532, 323–328 (2016).

  11. 11.

    et al. miRNA-126 orchestrates an oncogenic program in B cell precursor acute lymphoblastic leukemia. Cancer Cell 29, 905–921 (2016).

  12. 12.

    et al. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR–ABL leukemogenesis. Blood 105, 324–334 (2005).

  13. 13.

    et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev. Cell 15, 272–284 (2008).

  14. 14.

    et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev. Cell 15, 261–271 (2008).

  15. 15.

    , & Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA 10, 185–191 (2004).

  16. 16.

    , , , & Sprouty-related Ena–vasodilator-stimulated phosphoprotein-homology-1-domain-containing protein (SPRED1), a tyrosine protein phosphatase nonreceptor type 11 (SHP2) substrate in the Ras–extracellular-signal-regulated kinase (ERK) pathway. J. Biol. Chem. 286, 23102–23112 (2011).

  17. 17.

    , , & Role of Dicer and Drosha for endothelial microRNA expression and angiogenesis. Circ. Res. 101, 59–68 (2007).

  18. 18.

    , , & The multifactorial nature of microRNAs in vascular remodeling. Cardiovasc. Res. 110, 6–22 (2016).

  19. 19.

    et al. CD166 regulates human and murine hematopoietic stem cells and the hematopoietic niche. Blood 124, 519–529 (2014).

  20. 20.

    et al. Isolation of mouse mesenchymal stem cells on the basis of expression of Sca-1 and PDGFR-α. Nat. Protoc. 7, 2103–2111 (2012).

  21. 21.

    et al. The impact of disparate isolation methods for extracellular vesicles on downstream RNA profiling. J. Extracell. Vesicles 3, 24858 (2014).

  22. 22.

    et al. Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J. Extracell. Vesicles 2, 20360 (2013).

  23. 23.

    , , & BCR–ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells. Blood 103, 3167–3174 (2004).

  24. 24.

    , , , & ERK–BCL-2 pathway in the resistance of pancreatic cancer to anoikis. J. Surg. Res. 152, 18–25 (2009).

  25. 25.

    et al. Arteriolar niches maintain hematopoietic stem cell quiescence. Nature 502, 637–643 (2013).

  26. 26.

    & The chronic myeloid leukemia stem cell: stemming the tide of persistence. Blood 129, 1595–1606 (2017).

  27. 27.

    et al. MEK–ERK signaling pathway regulates the expression of Bcl-2, Bcl-X(L) and Mcl-1 and promotes survival of human pancreatic cancer cells. J. Cell. Biochem. 79, 355–369 (2000).

  28. 28.

    et al. Intracellular processing of immunostimulatory CpG-siRNA: Toll-like receptor 9 facilitates siRNA dicing and endosomal escape. J. Control. Release 170, 307–315 (2013).

  29. 29.

    et al. Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia. Blood 127, 1687–1700 (2016).

  30. 30.

    et al. The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor. Nature 456, 658–662 (2008).

  31. 31.

    et al. Endosomes are specialized platforms for bacterial sensing and NOD2 signaling. Nature 509, 240–244 (2014).

  32. 32.

    et al. Toll-like receptor 9 (TLR9) is present in murine liver sinusoidal endothelial cells (LSECs) and mediates the effect of CpG-oligonucleotides. J. Hepatol. 44, 939–946 (2006).

  33. 33.

    et al. Scavenger receptor expressed by endothelial cells I (SREC-I) mediates the uptake of acetylated low-density lipoproteins by macrophages stimulated with lipopolysaccharide. J. Biol. Chem. 279, 30938–30944 (2004).

  34. 34.

    , , & Identification and expression of scavenger receptor SR-BI in endothelial cells and smooth muscle cells of rat aorta in vitro and in vivo. Atherosclerosis 161, 95–103 (2002).

  35. 35.

    & Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5, 987–995 (2004).

  36. 36.

    , & Monitoring chronic myeloid leukemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br. J. Haematol. 107, 587–599 (1999).

  37. 37.

    , , & A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature 404, 193–197 (2000).

  38. 38.

    et al. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell 121, 1109–1121 (2005).

  39. 39.

    , , , & Abnormal function of the bone marrow microenvironment in chronic myelogenous leukemia: role of malignant stromal macrophages. Blood 85, 3636–3645 (1995).

  40. 40.

    et al. Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles. J. Extracell. Vesicles 3, 26913 (2014).

  41. 41.

    et al. Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia. Clin. Cancer Res. 19, 2355–2367 (2013).

Download references


We acknowledge the support of the Animal Resources Center, Analytical Cytometry, Pathology (Liquid Tumor), Bioinformatics, Electron Microscopy, Light Microscopy, Integrative Genomics and DNA/RNA Cores at City of Hope (COH) Comprehensive Cancer Center, which is supported by the National Cancer Institute (NCI) of the US National Institutes of Health (NIH) under award number P30CA33572. We thank C.J. Kuo (Stanford University) for the Mir126aflox/flox mice and are grateful to the COH Comprehensive Cancer Center, the Glasgow Experimental Cancer Medicine Centre and the SPIRIT trials, together with the patients and their physicians, for providing primary patient material for this study. This work was supported in part by NCI grants CA205247 (Y.-H.K.), CA102031 (G.M.), CA201184 (G.M.), CA213131 (M.K.), CA180861 (G.M.), CA158350 (G.M.), CA163800 (P.D.), and CA184411 (L.L.), the Gehr Family Foundation (G.M.), the George Hoag Family Foundation (G.M.), Cancer Research UK program grant C11074/A11008 (T.L.H.) and The Howat Foundation (T.L.H.).

Author information

Author notes

    • Bin Zhang
    •  & Le Xuan Truong Nguyen

    These authors contributed equally to this work.

    • Marcin Kortylewski
    • , Ya-Huei Kuo
    •  & Guido Marcucci

    These jointly directed this work.


  1. Gehr Family Center for Leukemia Research, Hematology Malignancies and Stem Cell Transplantation Institute, City of Hope Medical Center, Duarte, California, USA.

    • Bin Zhang
    • , Le Xuan Truong Nguyen
    • , Ling Li
    • , Dandan Zhao
    • , Bijender Kumar
    • , Herman Wu
    • , Allen Lin
    • , David S Snyder
    • , Haris Ali
    • , Anthony S Stein
    • , Casey Brewer
    • , Huafeng Wang
    • , Tinisha McDonald
    • , Piotr Swiderski
    • , Estelle Troadec
    • , Ching-Cheng Chen
    • , Vinod Pullarkat
    • , Yate-Ching Yuan
    • , Nadia Carlesso
    • , Stephen J Forman
    • , Ya-Huei Kuo
    •  & Guido Marcucci
  2. Department of Medical Biotechnology, Biotechnology Center of Ho Chi Minh City, Ho Chi Minh City, Vietnam.

    • Le Xuan Truong Nguyen
  3. Paul O' Gorman Leukemia Research Centre, College of Medical, Veterinary and Life Sciences, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.

    • Francesca Pellicano
    • , Lisa Hopcroft
    • , Mhairi Copland
    •  & Tessa L Holyoake
  4. Department of Immuno-oncology, City of Hope Medical Center, Duarte, California, USA.

    • Yu-Lin Su
    •  & Marcin Kortylewski
  5. Stanford University School of Medicine, Stanford, California, USA.

    • Calvin J Kuo
  6. University of Alabama at Birmingham, Birmingham, Alabama, USA.

    • Ravi Bhatia
  7. Department of Hematology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

    • Huafeng Wang
  8. Division of Hematology, Department of Internal Medicine, Ohio State University, Columbus, Ohio, USA.

    • Adrienne Dorrance
  9. Department of Medicine, Biochemistry and Molecular Biology and the Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine Baltimore, Baltimore, Maryland, USA.

    • Danilo Perrotti
  10. Deparment of Hematology, Hammersmith Hospital, Imperial College London, London, UK.

    • Danilo Perrotti


  1. Search for Bin Zhang in:

  2. Search for Le Xuan Truong Nguyen in:

  3. Search for Ling Li in:

  4. Search for Dandan Zhao in:

  5. Search for Bijender Kumar in:

  6. Search for Herman Wu in:

  7. Search for Allen Lin in:

  8. Search for Francesca Pellicano in:

  9. Search for Lisa Hopcroft in:

  10. Search for Yu-Lin Su in:

  11. Search for Mhairi Copland in:

  12. Search for Tessa L Holyoake in:

  13. Search for Calvin J Kuo in:

  14. Search for Ravi Bhatia in:

  15. Search for David S Snyder in:

  16. Search for Haris Ali in:

  17. Search for Anthony S Stein in:

  18. Search for Casey Brewer in:

  19. Search for Huafeng Wang in:

  20. Search for Tinisha McDonald in:

  21. Search for Piotr Swiderski in:

  22. Search for Estelle Troadec in:

  23. Search for Ching-Cheng Chen in:

  24. Search for Adrienne Dorrance in:

  25. Search for Vinod Pullarkat in:

  26. Search for Yate-Ching Yuan in:

  27. Search for Danilo Perrotti in:

  28. Search for Nadia Carlesso in:

  29. Search for Stephen J Forman in:

  30. Search for Marcin Kortylewski in:

  31. Search for Ya-Huei Kuo in:

  32. Search for Guido Marcucci in:


B.Z. and L.X.T.N. designed and conducted experiments, analyzed data and wrote the manuscript; L.L., D.Z., B.K., H. Wu, F.P., Y.-L.S., C.B., H. Wang, T.M. and E.T. conducted experiments; A.L., D.S.S., H.A. and A.S.S. provided samples and reviewed the patients' data; P.S. and M.K. designed the CpG–miR-126 inhibitor and reviewed data and the manuscript; L.H., C.-C.C., A.D., V.P., Y.-C.Y., D.P. and N.C. analyzed data; C.J.K. provided the miR-126 c-KO mouse model; R.B. provided the B6 SCLtTA×BCR–ABL mouse model of CML; M.C., T.L.H. and S.J.F. provided patient samples, designed experiments and reviewed the manuscript; M.K. and Y.-H.K. designed experiments, analyzed data and reviewed the manuscript; G.M. designed experiments, analyzed data, wrote the manuscript and provided administrative support.

Competing interests

The authors declare no competing financial interests.

Corresponding authors

Correspondence to Bin Zhang or Guido Marcucci.

Supplementary information

PDF files

  1. 1.

    Supplementary Figures

    Supplementary Figures 1–11

  2. 2.

    Life Sciences Reporting Summary